{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T01:01:56Z","timestamp":1794445316704,"version":"4.9.1"},"reference-count":96,"publisher":"Bentham Science Publishers Ltd.","issue":"9","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["MRMC"],"published-print":{"date-parts":[[2020,5,27]]},"abstract":"<jats:sec>\n                    <jats:title>:<\/jats:title>\n                    <jats:p>Parkinson's Disease (PD) is the second most common neurodegenerative disease in the elderly population, with a higher prevalence in men, independent of race and social class; it affects approximately 1.5 to 2.0% of the elderly population over 60 years and 4% for those over 80 years of age. PD is caused by the necrosis of dopaminergic neurons in the substantia nigra, which is the brain region responsible for the synthesis of the neurotransmitter dopamine (DA), resulting in its decrease in the synaptic cleft. The monoamine oxidase B (MAO-B) degrades dopamine, promoting the glutamate accumulation and oxidative stress with the release of free radicals, causing excitotoxicity. The PD symptoms are progressive physical limitations such as rigidity, bradykinesia, tremor, postural instability and disability in functional performance. Considering that there are no laboratory tests, biomarkers or imaging studies to confirm the disease, the diagnosis of PD is made by analyzing the motor features. There is no cure for PD, and the pharmacological treatment consists of a dopaminergic supplement with levodopa, COMT inhibitors, anticholinergics agents, dopaminergic agonists, and inhibitors of MAO-B, which basically aims to control the symptoms, enabling better functional mobility and increasing life expectancy of the treated PD patients. Due to the importance and increasing prevalence of PD in the world, this study reviews information on the pathophysiology, symptomatology as well as the most current and relevant treatments of PD patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/1389557519666191104110908","type":"journal-article","created":{"date-parts":[[2019,11,5]],"date-time":"2019-11-05T06:13:10Z","timestamp":1572934390000},"page":"754-767","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":221,"title":["Parkinson\u2019s Disease: A Review from Pathophysiology to Treatment"],"prefix":"10.2174","volume":"20","author":[{"given":"Bianca L.B.","family":"Marino","sequence":"first","affiliation":[{"name":"Laboratorio de Quimica Farmaceutica e Medicinal (PharMedChem), Universidade Federal do Amapa, Macapa, Amapa, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucilene R.","family":"de Souza","sequence":"additional","affiliation":[{"name":"Laboratorio de Quimica Farmaceutica e Medicinal (PharMedChem), Universidade Federal do Amapa, Macapa, Amapa, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kessia P.A.","family":"Sousa","sequence":"additional","affiliation":[{"name":"Laboratorio de Quimica Farmaceutica e Medicinal (PharMedChem), Universidade Federal do Amapa, Macapa, Amapa, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9355-9342","authenticated-orcid":true,"given":"Jaderson V.","family":"Ferreira","sequence":"additional","affiliation":[{"name":"Laboratorio de Quimica Farmaceutica e Medicinal (PharMedChem), Universidade Federal do Amapa, Macapa, Amapa, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3794-9389","authenticated-orcid":true,"given":"Elias C.","family":"Padilha","sequence":"additional","affiliation":[{"name":"Faculdade de Ciencias Farmaceuticas, Universidade Estadual Paulista (UNESP), Campus Araraquara, Departamento de Principios Ativos Naturais e Toxicologia, Araraquara, Sao Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6049-3650","authenticated-orcid":true,"given":"Carlos H.T.P.","family":"da Silva","sequence":"additional","affiliation":[{"name":"Department of Chemistry, School of Philosophy, Sciences and Letters of Ribeirao Preto, University of Sao Paulo, Ribeirao Preto, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlton A.","family":"Taft","sequence":"additional","affiliation":[{"name":"Centro Brasileiro de Pesquisas Fisicas, Rio de Janeiro, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7851-7363","authenticated-orcid":true,"given":"Lorane I.S.","family":"Hage-Melim","sequence":"additional","affiliation":[{"name":"Laboratorio de Quimica Farmaceutica e Medicinal (PharMedChem), Universidade Federal do Amapa, Macapa, Amapa, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.nbd.2018.11.004","volume":"124","author":"Ikeda-Matsuo Y.","year":"2019","unstructured":"Ikeda-Matsuo Y.; Miyata H.; Mizoguchi T.; Ohama E.; Naito Y.; Uematsu S.; Akira S.; Sasaki Y.; Tanabe M.; Microsomal prostaglandin E synthase-1 is a critical factor in dopaminergic neurodegeneration in Parkinson\u2019s disease. Neurobiol Dis 2019,124,81-92","journal-title":"Neurobiol Dis"},{"key":"ref=2","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.neuint.2018.11.005","volume":"122","author":"Miyanishi K.","year":"2019","unstructured":"Miyanishi K.; Choudhury M.E.; Watanabe M.; Kubo M.; Nomoto M.; Yano H.; Tanaka J.; Behavioral tests predicting striatal dopamine level in a rat hemi-Parkinson\u2019s disease model. Neurochem Int 2019,122,38-46","journal-title":"Neurochem Int"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2174\/187152711794480429","volume":"10","author":"Rocha M.D.","year":"2011","unstructured":"Rocha M.D.; Viegas F.P.; Campos H.C.; Nicastro P.C.; Fossaluzza P.C.; Fraga C.A.; Barreiro E.J.; Viegas C.; The role of natural products in the discovery of new drug candidates for the treatment of neurodegenerative disorders II: Alzheimer\u2019s disease. CNS Neurol Disord Drug Targets 2011,10(2),251-270","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=4","author":"Santos V.L.","year":"2015","unstructured":"Santos V.L.; Perfil epidemiol\u00f3gico da doen\u00e7a de Parkinson no Brasil, Centro universit\u00e1rio de Bras\u00edlia., 2015"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2017\/7893975","volume":"2017","author":"Barbosa A.F.","year":"2017","unstructured":"Barbosa A.F.; Voos M.C.; Chen J.; Francato D.C.V.; Souza C.O.; Barbosa E.R.; Chien H.F.; Mansur L.L.; Cognitive or cognitive-motor executive function tasks? Evaluating verbal fluency measures in people with parkinson\u2019s disease. BioMed Res Int 2017,2017,1-7","journal-title":"BioMed Res Int"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.parkreldis.2006.07.003","volume":"13","author":"Tan L.C.","year":"2007","unstructured":"Tan L.C.; Venketasubramanian N.; Jamora R.D.; Heng D.; Incidence of Parkinson\u2019s disease in Singapore. Parkinsonism Relat Disord 2007,13(1),40-43","journal-title":"Parkinsonism Relat Disord"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fnagi.2016.00065","volume":"8","author":"Song J.","year":"2016","unstructured":"Song J.; Kim J.; Degeneration of dopaminergic neurons due to metabolic alterations and Parkinson\u2019s Disease. Front Aging Neurosci 2016,8(65),1-11","journal-title":"Front Aging Neurosci"},{"key":"ref=8","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1590\/S1516-44462008000400013","volume":"30","author":"Caixeta L.","year":"2008","unstructured":"Caixeta L.; Vieira R.T.; Dem\u00eancia na Doen\u00e7a de Parkinson. Rev Bras Psiquiatr 2008,30(4),375-383","journal-title":"Rev Bras Psiquiatr"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2188\/jea.JE20081034","volume":"19","author":"Muangpaisan W.","year":"2009","unstructured":"Muangpaisan W.; Hori H.; Brayne C.; Systematic review of the prevalence and incidence of Parkinson\u2019s Disease in Asia. J Epidemiol 2009,19(6),281-293","journal-title":"J Epidemiol"},{"key":"ref=10","first-page":"231","volume":"18","author":"Tan L.C.S.","year":"2013","unstructured":"Tan L.C.S.; Epidemiology of Parkinson\u2019s disease. Neurol Asia 2013,18(3),231-238","journal-title":"Neurol Asia"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1474-4422(06)70471-9","volume":"5","author":"Lau L.M.L.","year":"2006","unstructured":"Lau L.M.L.; Breteler M.M.B.; Epidemiology of Parkinson\u2019s disease. Lancet Neurol 2006,5(6),525-535","journal-title":"Lancet Neurol"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.parkreldis.2015.12.008","volume":"23","author":"Bellou V.","year":"2016","unstructured":"Bellou V.; Belbasis L.; Tzoulaki I.; Evangelou E.; Ioannidis J.P.A.; Environmental risk factors and Parkinson\u2019s disease: An umbrella review of meta-analyses. Parkinsonism Relat Disord 2016,23,1-9","journal-title":"Parkinsonism Relat Disord"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jns.2016.02.066","volume":"364","author":"Onozawa R.","year":"2016","unstructured":"Onozawa R.; Tsugawa J.; Tsuboi Y.; Fukae J.; Mishima T.; Fujioka S.; The impact of early morning off in Parkinson\u2019s disease on patient quality of life and caregiver burden. J Neurol Sci 2016,364,1-5","journal-title":"J Neurol Sci"},{"key":"ref=14","first-page":"387","volume":"5","author":"Pereira M.C.L.","year":"2007","unstructured":"Pereira M.C.L.; Suzuki D.E.; Janjoppi L.; Okamoto O.K.; Strategies for neuronal recovery in experimental models of Parkinson\u2019s disease. Einstein 2007,5(4),387-391","journal-title":"Einstein"},{"key":"ref=15","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/mdc3.12568","volume":"5","author":"Abbas M.M.","year":"2017","unstructured":"Abbas M.M.; Xu Z.; Tan L.C.S.; Epidemiology of Parkinson\u2019s Disease-East Versus West. Mov Disord Clin Pract 2017,5(1),14-28","journal-title":"Mov Disord Clin Pract"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1212\/01.wnl.0000247740.47667.03","volume":"68","author":"Dorsey E.R.","year":"2007","unstructured":"Dorsey E.R.; Constantinescu R.; Thompson J.P.; Biglan K.M.; Holloway R.G.; Kieburtz K.; Marshall F.J.; Ravina B.M.; Schifitto G.; Siderowf A.; Tanner C.M.; Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007,68(5),384-386","journal-title":"Neurology"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1021\/acschemneuro.6b00440","volume":"8","author":"Huot P.","year":"2017","unstructured":"Huot P.; Sgambato-Faure V.; Fox S.H.; McCreary A.C.; Serotonergic approaches in Parkinson\u2019s Disease: Translational perspectives, an update. ACS Chem Neurosci 2017,8(5),973-986","journal-title":"ACS Chem Neurosci"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.cortex.2018.01.010","volume":"100","author":"Gallese V.","year":"2018","unstructured":"Gallese V.; Cuccio V.; The neural exploitation hypothesis and its implications for an embodied approach to language and cognition: Insights from the study of action verbs processing and motor disorders in Parkinson\u2019s disease. Cortex 2018,100,215-225","journal-title":"Cortex"},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","volume":"24","author":"Braak H.","year":"2003","unstructured":"Braak H.; Del Tredici K.; R\u00fcb U.; de Vos R.A.; Jansen Steur E.N.; Braak E.; Staging of brain pathology related to sporadic Parkinson\u2019s disease. Neurobiol Aging 2003,24(2),197-211","journal-title":"Neurobiol Aging"},{"key":"ref=20","doi-asserted-by":"crossref","first-page":"289","DOI":"10.3389\/fnins.2018.00289","volume":"12","author":"Wise Jr","year":"2018","unstructured":"Wise Jr; Price C.G.; Amaro J.A.; Cannon J.R.; Autophagy disruptions associated with altered optineurin expression in extranigral regions in a rotenone model of Parkinson\u2019s Disease. Front Neurosci 2018,12,289","journal-title":"Front Neurosci"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jns.2016.02.017","volume":"363","author":"Silva P.G.C.","year":"2016","unstructured":"Silva P.G.C.; Domingues D.D.; Carvalho L.A.; Allodi S.; Correa C.L.; Neurotrophic factors in Parkinson\u2019s disease are regulated by exercise: Evidence-based pactice. J Neurol Sci 2016,363,5-15","journal-title":"J Neurol Sci"},{"key":"ref=22","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1007\/s00702-018-1942-9","volume":"125","author":"Youdim M.B.H.","year":"2018","unstructured":"Youdim M.B.H.; Monoamine oxidase inhibitors, and iron chelators in depressive illness and neurodegenerative diseases. J Neural Transm (Vienna) 2018,125(11),1719-1733","journal-title":"J Neural Transm (Vienna)"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1148\/rg.345140009","volume":"34","author":"Broski S.M.","year":"2014","unstructured":"Broski S.M.; Hunt C.H.; Johnson G.B.; Morreale R.F.; Lowe V.J.; Peller P.J.; Structural and functional imaging in parkinsonian syndromes. Radiographics 2014,34(5),1273-1292","journal-title":"Radiographics"},{"key":"ref=24","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1007\/s00415-017-8588-7","volume":"264","author":"Choudhry H.","year":"2017","unstructured":"Choudhry H.; Perlmuter L.C.; Non CNS pathogenic origin of Parkinson\u2019s disease. J Neurol 2017,264(9),2027-2030","journal-title":"J Neurol"},{"key":"ref=25","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.mehy.2017.02.007","volume":"101","author":"Mori I.","year":"2017","unstructured":"Mori I.; Viremic attack explains the dual-hit theory of Parkinson\u2019s disease. Med Hypotheses 2017,101,33-36","journal-title":"Med Hypotheses"},{"key":"ref=26","doi-asserted-by":"crossref","first-page":"II3","DOI":"10.1007\/PL00007758","volume":"247","author":"Braak H.","year":"2000","unstructured":"Braak H.; Braak E.; Pathoanatomy of Parkinson\u2019s disease. J Neurol 2000,247(Suppl. 2),II3-II10","journal-title":"J Neurol"},{"key":"ref=27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12938-017-0432-x","volume":"17","author":"Butt A.H.","year":"2018","unstructured":"Butt A.H.; Rovini E.; Dolciotti C.; De Petris G.; Bongioanni P.; Carboncini M.C.; Cavallo F.; Objective and automatic classification of Parkinson disease with Leap Motion controller. Biomed Eng Online 2018,17(168),1-21","journal-title":"Biomed Eng Online"},{"key":"ref=28","doi-asserted-by":"crossref","first-page":"50","DOI":"10.17116\/jnevro201811806250","volume":"118","author":"Mironova Y.S.","year":"2018","unstructured":"Mironova Y.S.; Zhukova I.A.; Zhukova N.G.; Alifirova V.M.; Izhboldina O.P.; Latypova A.V.; Parkinson's disease and glutamate excitotoxicity. Zh Nevrol Psikhiatr Im S S Korsakova, 2018,118(6. Vyp. 2),50-54","journal-title":"Zh Nevrol Psikhiatr Im S S Korsakova,"},{"key":"ref=29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fneur.2019.00122","volume":"10","author":"Caggiu E.","year":"2019","unstructured":"Caggiu E.; Arru G.; Hosseini S.; Niegowska M.; Sechi G.; Zarbo I.R.; Sechi L.A.; Inflammation, Infectious Triggers, and Parkinson\u2019s Disease. Front Neurol 2019,10(122),1-9","journal-title":"Front Neurol"},{"key":"ref=30","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","volume":"386","author":"Kalia L.V.","year":"2015","unstructured":"Kalia L.V.; Lang A.E.; Parkinson\u2019s disease. Lancet 2015,386(9996),896-912","journal-title":"Lancet"},{"key":"ref=31","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.molbrainres.2005.08.014","volume":"141","author":"McKinley E.T.","year":"2005","unstructured":"McKinley E.T.; Baranowski T.C.; Blavo D.O.; Cato C.; Doan T.N.; Rubinstein A.L.; Neuroprotection of MPTP-induced toxicity in zebrafish dopaminergic neurons. Brain Res Mol Brain Res 2005,141(2),128-137","journal-title":"Brain Res Mol Brain Res"},{"key":"ref=32","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s10072-018-3585-x","volume":"40","author":"Kaur R.","year":"2019","unstructured":"Kaur R.; Mehan S.; Singh S.; Understanding multifactorial architecture of Parkinson\u2019s disease: Pathophysiology to management. Neurol Sci 2019,40(1),13-23","journal-title":"Neurol Sci"},{"key":"ref=33","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1080\/07391102.2008.10507183","volume":"25","author":"Braun G.H.","year":"2008","unstructured":"Braun G.H.; Jorge D.M.M.; Ramos H.P.; Alves R.M.; da Silva V.B.; Giuliatti S.; Sampaio S.V.; Taft C.A.; Silva C.H.T.P.; Molecular dynamics, flexible docking, virtual screening, ADMET predictions, and molecular interaction field studies to design novel potential MAO-B inhibitors. J Biomol Struct Dyn 2008,25(4),347-355","journal-title":"J Biomol Struct Dyn"},{"key":"ref=34","doi-asserted-by":"crossref","first-page":"40","DOI":"10.2174\/187794680601160324121146","volume":"6","author":"Souza L.R.","year":"2016","unstructured":"Souza L.R.; Pican\u00e7o R.M.; Pinheiro A.A.; Silva K.R.; Taft C.A.; da Silva C.H.T. de P.; Santos C.B.; Hage-Melim L.I.S.; Development of Monoamine Oxidase B inhibitors with Antiparkinson activity. Curr Phys Chem 2016,6,40-52","journal-title":"Curr Phys Chem"},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"551","DOI":"10.3390\/ijms18030551","volume":"18","author":"Cacabelos R.","year":"2017","unstructured":"Cacabelos R.; Parkinson\u2019s disease: From pathogenesis to pharmacogenomics. Int J Mol Sci 2017,18(3),551","journal-title":"Int J Mol Sci"},{"key":"ref=36","first-page":"1","volume":"13","author":"Liu C.","year":"2019","unstructured":"Liu C.; Liang M.C.; Soong T.W.; Nitric Oxide, Iron and Neurodegeneration. Front Neurosci 2019,13(114),1-10","journal-title":"Front Neurosci"},{"key":"ref=37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fnagi.2017.00020","volume":"9","author":"Reden\u0161ek S.","year":"2017","unstructured":"Reden\u0161ek S.; Tro\u0161t M.; Dol\u017ean V.; Genetic determinants of Parkinson\u2019s Disease: Can they help to stratify the patients based on the underlying molecular defect? Front Aging Neurosci 2017,9(20),1-17","journal-title":"Front Aging Neurosci"},{"key":"ref=38","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1002\/mds.27506","volume":"33","author":"Picillo M.","year":"2018","unstructured":"Picillo M.; Lizarraga K.J.; Friesen E.L.; Chau H.; Zhang M.; Sato C.; Rooke G.; Munhoz R.P.; Rogaeva E.; Fraser P.E.; Kalia S.K.; Kalia L.V.; Parkinsonism due to A53E \u03b1-synuclein gene mutation: Clinical, genetic, epigenetic, and biochemical features. Mov Disord 2018,33(12),1950-1955","journal-title":"Mov Disord"},{"key":"ref=39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2019.00008","volume":"10","author":"Reden\u0161ek S.","year":"2019","unstructured":"Reden\u0161ek S.; Flisar D.; Kojovic M.; Kramberger M.G.; Georgiev D.; Pirto\u0161ek Z.; Tro\u0161t M.; Dol\u017ean V.; Dopaminergic pathway genes influence adverse events related to dopaminergic treatment in Parkinson\u2019s disease. Front Pharmacol 2019,10(8),1-10","journal-title":"Front Pharmacol"},{"key":"ref=40","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s11910-018-0860-4","volume":"18","author":"Gan-Or Z.","year":"2018","unstructured":"Gan-Or Z.; Liong C.; Alcalay R.N.; GBA-Associated Parkinson\u2019s disease and other synucleinopathies. Curr Neurol Neurosci 2018,18(8),44","journal-title":"Curr Neurol Neurosci"},{"key":"ref=41","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1056\/NEJM2003ra020003","volume":"348","author":"Nussbaum R.L.","year":"2003","unstructured":"Nussbaum R.L.; Ellis C.E.; Alzheimer\u2019s disease and Parkinson\u2019s disease. N Engl J Med 2003,348,1356-1364","journal-title":"N Engl J Med"},{"key":"ref=42","doi-asserted-by":"crossref","first-page":"3338","DOI":"10.1523\/JNEUROSCI.0285-07.2007","volume":"27","author":"Periquet M.","year":"2007","unstructured":"Periquet M.; Fulga T.; Myllykangas L.; Schlossmacher M.G.; Feany M.; Aggregated alpha-synuclein mediates dopaminergic neurotoxicity in vivo. J Neurosci 2007,27(12),3338-3346","journal-title":"J Neurosci"},{"key":"ref=43","doi-asserted-by":"crossref","first-page":"9799","DOI":"10.1523\/JNEUROSCI.1787-16.2017","volume":"37","author":"Surmeier D.J.","year":"2017","unstructured":"Surmeier D.J.; Obeso J.A.; Halliday G.M.; Parkinson\u2019s disease is not simply a prion disorder. J Neurosci 2017,37(41),9799-9807","journal-title":"J Neurosci"},{"key":"ref=44","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.artmed.2016.01.004","volume":"67","author":"Drot\u00e1r P.","year":"2016","unstructured":"Drot\u00e1r P.; Mekyska J.R.; Rektorov\u00e1 I.; Masarov\u00e1 L.; Sm\u00e9kal Z.; Faundez-Zanuy M.; Evaluation of handwriting kinematics and pressure for differential diagnosis of Parkinson\u2019s disease. Artif Intell Med 2016,67,39-46","journal-title":"Artif Intell Med"},{"key":"ref=45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fnmol.2018.00001","volume":"11","author":"Wei Z.","year":"2018","unstructured":"Wei Z.; Li X.; Li X.; Liu Q.; Cheng Y.; Oxidative stress in Parkinson\u2019s disease: A systematic review and meta-analysis. Front Mol Neurosci 2018,11(236),1-7","journal-title":"Front Mol Neurosci"},{"key":"ref=46","first-page":"3250","volume":"71","author":"Costa M.F.B.N.A.","year":"2018","unstructured":"Costa M.F.B.N.A.; Reisdorfer E.; Kempfer S.S.; Porporatti A.L.; Canto G.L.; Validade diagn\u00f3stica de biomarcadores na doen\u00e7a de Parkinson: Revis\u00e3o sistem\u00e1tica e meta-an\u00e1lise. Ver Bras Enferm 2018,71(6),3250-3259","journal-title":"Ver Bras Enferm"},{"key":"ref=47","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1002\/mds.25772","volume":"29","author":"Parnetti L.","year":"2014","unstructured":"Parnetti L.; Chiasserini D.; Persichetti E.; Eusebi P.; Varghese S.; Qureshi M.M.; Dardis A.; Deganuto M.; De Carlo C.; Castrioto A.; Balducci C.; Paciotti S.; Tambasco N.; Bembi B.; Bonanni L.; Onofrj M.; Rossi A.; Beccari T.; El-Agnaf O.; Calabresi P.; Cerebrospinal fluid lysosomal enzymes and alpha-synuclein in Parkinson\u2019s disease. Mov Disord 2014,29(8),1019-1027","journal-title":"Mov Disord"},{"key":"ref=48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fnins.2016.00008","volume":"10","author":"Kuhbach K.","year":"2016","unstructured":"Kuhbach K.; H\u00fclsemann M.; Herrmann Y.; Kravchenko K.; Kulawik A.; Linnartz C.; Peters L.; Wang K.; Willbold J.; Willbold D.; Bannach O.; Application of an amyloid beta oligomer standard in the sFIDA assay. Front Neurosci 2016,10(8),1-6","journal-title":"Front Neurosci"},{"key":"ref=49","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1136\/jnnp.51.6.745","volume":"51","author":"Gibb W.R.G.","year":"1988","unstructured":"Gibb W.R.G.; Lees A.J.; The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 1988,51(6),745-752","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=50","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1002\/mds.27305","volume":"33","author":"Argaud S.","year":"2018","unstructured":"Argaud S.; Verin M.; Sauleau P.; Grandjean D.; Facial Emotion Recognition in Parkinson\u2019s disease: A review and new hypotheses. Mov Disord 2018,33(4),554-567","journal-title":"Mov Disord"},{"key":"ref=51","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"Postuma R.B.","year":"2015","unstructured":"Postuma R.B.; Berg D.; Stern M.; Poewe W.; Olanow C.W.; Oertel W.; Obeso J.; Marek K.; Litvan I.; Lang A.E.; Halliday G.; Goetz C.G.; Gasser T.; Dubois B.; Chan P.; Bloem B.R.; Adler C.H.; Deuschl G.; MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov Disord 2015,30(12),1591-1601","journal-title":"Mov Disord"},{"key":"ref=52","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1007\/s00415-018-8969-6","volume":"265","author":"Hustad E.","year":"2018","unstructured":"Hustad E.; Skogholt A.H.; Hveem K.; Aasly J.O.; The accuracy of the clinical diagnosis of Parkinson disease. The HUNT study. J Neurol 2018,265(9),2120-2124","journal-title":"J Neurol"},{"key":"ref=53","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1590\/S0004-282X2010000600020","volume":"68","author":"Basorttini O.G.P.","year":"2010","unstructured":"Basorttini O.G.P.; Fel\u00edcio A.C.; Aquino C.C.H.A.; Pedroso J.L.; Progressive supranuclear palsy: New concepts. Arq Neuropsiquiatr 2010,68(6),938-946","journal-title":"Arq Neuropsiquiatr"},{"key":"ref=54","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s00441-017-2734-5","volume":"373","author":"Glaab E.","year":"2018","unstructured":"Glaab E.; Computational systems biology approaches for Parkinson\u2019s disease. Cell Tissue Res 2018,373(1),91-109","journal-title":"Cell Tissue Res"},{"key":"ref=55","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1590\/0100-3984.2016-0073","volume":"50","year":"2017","unstructured":"Oliveira1, R.V.; Pereira, J.S. O papel da difus\u00e3o por resson\u00e2ncia magn\u00e9tica na doen\u00e7a de Parkinson e no diagn\u00f3stico diferencial com parkinsonismo at\u00edpico. Radiol Bras 2017,50(4),250-257","journal-title":"Radiol Bras"},{"key":"ref=56","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.acra.2010.09.022","volume":"18","author":"Modrego P.J.","year":"2011","unstructured":"Modrego P.J.; Fayed N.; Artal J.; Correlation of findings in advanced MRI techniques with global severity scales in patients with Parkinson disease. Acad Radiol 2011,18(2),235-241","journal-title":"Acad Radiol"},{"key":"ref=57","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3171\/2016.10.JNS16758","volume":"128","author":"Zaaroor M.","year":"2018","unstructured":"Zaaroor M.; Sinai A.; Goldsher D.; Eran A.; Nassar M.; Schelensiger I.; Magnetic resonance-guided focused ultrasound thalamotomy for tremor: A report of 30 Parkinson\u2019s disease and essential tremor cases. J Neurosurg 2018,128(1),202-210","journal-title":"J Neurosurg"},{"key":"ref=58","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/NRL.0b013e318183fdd8","volume":"15","author":"Felicio A.C.","year":"2009","unstructured":"Felicio A.C.; Shih M.C.; Cordeiro-Junior C.; Andrade L.A.F.; Molecular imaging studies in Parkinson\u2019s disease: Reducing diagnostic uncertainty. Neurologist 2009,15(1),6-16","journal-title":"Neurologist"},{"key":"ref=59","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.bbadis.2008.10.003","volume":"1792","author":"Pavese N.","year":"2009","unstructured":"Pavese N.; Brooks D.J.; Imaging neurodegeneration in Parkinson\u2019s disease. Biochim Biophys Acta 2009,1792(7),722-729","journal-title":"Biochim Biophys Acta"},{"key":"ref=60","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/nrneurol.2010.78","volume":"6","author":"Foulds P.","year":"2010","unstructured":"Foulds P.; Mann D.M.A.; Mitchell J.D.; Allsop D.; Parkinson disease: Progress toward a molecular biomarker for Parkinson disease. Nat Rev Neurol 2010,6(7),359-361","journal-title":"Nat Rev Neurol"},{"key":"ref=61","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.3390\/ijms18122698","volume":"18","author":"Leggio L.","year":"2017","unstructured":"Leggio L.; Vivarelli S.; L\u2019Episcopo L.; Tirolo C.; Caniglia S.; Testa N.; Marchetti B.; Iraci N.; microRNAs in Parkinson\u2019s disease: From pathogenesis to novel diagnostic and therapeutic approaches. Int J Mol Sci 2017,18(12),2698","journal-title":"Int J Mol Sci"},{"key":"ref=62","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s00228-015-1881-4","volume":"71","author":"Crispo J.A.G.","year":"2015","unstructured":"Crispo J.A.G.; Fortin Y.; Thibault D.P.; Emons M.; Bjerre L.M.; Kohen D.E.; Perez-Lloret S.; Mattison D.; Willis A.W.; Krewski D.L.; Trends in inpatient antiparkinson drug use in the USA, 2001-2012. Eur J Clin Pharmacol 2015,71(8),1011-1019","journal-title":"Eur J Clin Pharmacol"},{"key":"ref=63","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1093\/brain\/awu107","volume":"137","author":"Francardo V.","year":"2014","unstructured":"Francardo V.; Bez F.; Wieloch T.; Nissbrandt H.; Ruscher K.; Cenci M.A.; Pharmacological stimulation of sigma-1 receptors has neurorestorative effects in experimental parkinsonism. Brain 2014,137(Pt 7),1998-2014","journal-title":"Brain"},{"key":"ref=64","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1002\/mds.26078","volume":"30","author":"Poewe W.","year":"2015","unstructured":"Poewe W.; Antonini A.; Novel formulations and modes of delivery of levodopa. Mov Disord 2015,30(1),114-120","journal-title":"Mov Disord"},{"key":"ref=65","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/tpj.2016.79","volume":"18","author":"Rieck M.","year":"2018","unstructured":"Rieck M.; Schumacher-Schuh A.F.; Atmann V.; Callegari-Jacques S.M.; Rieder C.R.M.; Hutz M.H.; Association between DRD2 and DRD3 gene polymorphisms and gastrointestinal symptoms induced by levodopa therapy in Parkinson\u2019s disease. Pharmacogenomics J 2018,18(1),196-200","journal-title":"Pharmacogenomics J"},{"key":"ref=66","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1080\/14656566.2018.1538355","volume":"19","author":"M\u00fcller T.","year":"2018","unstructured":"M\u00fcller T.; M\u00f6hr J.D.; Efficacy of carbidopa-levodopa extended-release capsules (IPX066) in the treatment of Parkinson disease. Expert Opin Pharmacother 2018,19(18),2063-2071","journal-title":"Expert Opin Pharmacother"},{"key":"ref=67","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1042\/BCJ20170728","volume":"474","author":"Safe S.","year":"2017","unstructured":"Safe S.; Carbidopa: A selective Ah receptor modulator (SAhRM). Biochem J 2017,474(22),3763-3765","journal-title":"Biochem J"},{"key":"ref=68","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1002\/mds.27340","volume":"33","author":"Antonini A.","year":"2018","unstructured":"Antonini A.; Moro E.; Godeiro C.; Reichmann H.; Medical and surgical management of advanced Parkinson\u2019s disease. Mov Disord 2018,33(6),900-908","journal-title":"Mov Disord"},{"key":"ref=69","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.neulet.2016.04.015","volume":"621","author":"Shin M.S.","year":"2016","unstructured":"Shin M.S.; Meong H.Y.; An D.I.; Lee H.Y.; Sung I.H.; Treadmill exercise facilitates synaptic plasticity on dopaminergic neurons and fibers in the mouse model with Parkinson\u2019s disease. Neurosci Lett 2016,621,28-33","journal-title":"Neurosci Lett"},{"key":"ref=70","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.expneurol.2017.09.005","volume":"298","author":"K\u00fchn J.","year":"2017","unstructured":"K\u00fchn J.; Haumesser J.K.; Beck M.H.; Altsch\u00fcler J.; K\u00fchn A.A.; Nikulin V.V.; Riesen C.; Differential effects of levodopa and apomorphine on neuronal population oscillations in the cortico-basal ganglia loop circuit in vivo in experimental parkinsonism. Exp Neurol, 2017,298(Pt A),122-133","journal-title":"Exp Neurol,"},{"key":"ref=71","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00702-015-1441-1","volume":"123","author":"Reichmann H.","year":"2016","unstructured":"Reichmann H.; Modern treatment in Parkinson\u2019s disease, a personal approach. J Neural Transm (Vienna) 2016,123(1),73-80","journal-title":"J Neural Transm (Vienna)"},{"key":"ref=72","first-page":"202","volume":"18","author":"Pastor P.","year":"2003","unstructured":"Pastor P.; Tolosa E.; Cabergoline in the treatment of Parkinson\u2019s disease. Neurologia 2003,18(4),202-209","journal-title":"Neurologia"},{"key":"ref=73","first-page":"471","volume":"88","author":"Gopinathan G.","year":"1989","unstructured":"Gopinathan G.; Horowski R.; Suchy I.H.; Lisuride pharmacology and treatment of Parkinson\u2019s disease. In Calne DB (Ed.) Drugs for the treatment of Parkinson\u2019s disease, Handbook of Experimental Pharmacology,1989,88,471-513"},{"key":"ref=74","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s00702-014-1314-z","volume":"122","author":"Italiano D.","year":"2015","unstructured":"Italiano D.; Bianchini E.; Ilardi M.; Cilia R.; Pezzoli G.; Zanettini R.; Vacca L.; Stocchi F.; Bramanti P.; Ciurleo R.; Di Lorenzo G.; Polimeni G.; de Luise C.; Ross D.; Rijnbeek P.; Sturkenboom M.; Trifir\u00f2 G.; Effectiveness of risk minimization measures for cabergoline-induced cardiac valve fibrosis in clinical practice in Italy. J Neural Transm (Vienna) 2015,122(6),799-808","journal-title":"J Neural Transm (Vienna)"},{"key":"ref=75","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/BF00886877","volume":"243","author":"Pondal M.","year":"1996","unstructured":"Pondal M.; Teodoro D.S.; Bermejo F.; Anticholinergic therapy and dementia in patients with Parkinson\u2019s disease. J Neurol 1996,243(7),543-545","journal-title":"J Neurol"},{"key":"ref=76","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/j.1742-1241.2002.tb11298.x","volume":"56","author":"Porter M.C.","year":"2002","unstructured":"Porter M.C.; Apprah-Kubf L.S.; Chaudhuri K.R.; Treatment of Parkinson\u2019s disease and restless legs syndrome with cabergoline, a long-acting dopamine agonist. Int J Clin Pract 2002,56(6),468-474","journal-title":"Int J Clin Pract"},{"key":"ref=77","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.18549\/PharmPract.2018.04.1220","volume":"16","author":"Faddoul L.","year":"2018","unstructured":"Faddoul L.; Chahine B.; Haydar S.; Abourida S.; Hallit S.; Raad E.; The effect of pramipexole extended release on the levodopa equivalent daily dose in Lebanese Parkinson diseased patients. Pharm Pract (Granada) 2018,16(4),1220","journal-title":"Pharm Pract (Granada)"},{"key":"ref=78","doi-asserted-by":"crossref","first-page":"635","DOI":"10.3109\/21691401.2016.1167703","volume":"45","author":"Pardeshi C.V.","year":"2017","unstructured":"Pardeshi C.V.; Belgamwar V.S.; Ropinirole-dextran sulfate nanoplex for nasal administration against Parkinson\u2019s disease: In silico molecular modeling and in vitro ex vivo evaluation. Artif Cells Nanomed Biotechnol 2017,45(3),635-648","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"ref=79","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1472-8206.2012.01028.x","volume":"27","author":"Perez-Lloret S.","year":"2013","unstructured":"Perez-Lloret S.; Rey M.V.; Ratti P.L.; Rascol O.; Rotigotine transdermal patch for the treatment of Parkinson\u2019s Disease. Fundam Clin Pharmacol 2013,27(1),81-95","journal-title":"Fundam Clin Pharmacol"},{"key":"ref=80","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.3233\/JPD-181476","volume":"8","author":"van Wamelen D.J.V.","year":"2018","unstructured":"van Wamelen D.J.V.; Grigorioud S.; Chaudhuri K.R.; Odin P.; Continuous drug delivery aiming continuous dopaminergic stimulation in Parkinson\u2019s disease. J Parkinsons Dis 2018,8(Suppl. 1),S65-S72","journal-title":"J Parkinsons Dis"},{"key":"ref=81","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1002\/jcph.1394","volume":"59","author":"Santos E.U.D.","year":"2019","unstructured":"Santos E.U.D.; Duarte E.B.C.; Miranda L.M.R.; Asano A.G.C.; Asano N.M.J.; Maia M.M.D.; Souza P.R.E.; Pharmacogenetic profile and the occurrence of visual hallucinations in patients with sporadic Parkinson\u2019s disease. J Clin Pharmacol 2019,59(7),1006-1013","journal-title":"J Clin Pharmacol"},{"key":"ref=82","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0001616","volume":"3","author":"Mallajosyula J.K.","year":"2008","unstructured":"Mallajosyula J.K.; Deepinder K.; Shankar J.C.; Subramanian R.; Anand R.; Nicholls D.G.; Di Monte D.A.; Macarthur H.; Andersen J.K.; MAO-B Elevation in mouse brain astrocytes results in Parkinson\u2019s pathology. PLoS One 2008,3(2)","journal-title":"PLoS One"},{"key":"ref=83","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1080\/01616412.2017.1297911","volume":"39","author":"Liu B.","year":"2017","unstructured":"Liu B.; Chaonan L.; Zhang J.; Liu Y.; Sun J.; Cheng X.; Mao W.; Ma Y.; Li S.; Effects of eldepryl on glial cell proliferation and activation in the substantia nigra and striatum in a rat model of Parkinson\u2019s disease. Neurol Res 2017,39(5),459-467","journal-title":"Neurol Res"},{"key":"ref=84","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1056\/NEJMoa0809335","volume":"361","author":"Olanow C.W.","year":"2009","unstructured":"Olanow C.W.; Rascol O.; Hauser R.; Feigin P.; Jankovic J.; Lang A.; Langston W.; Melamed E.; Poewe W.; Stocchi F.; Tolosa E.; A double-blind, delayed-start trial of rasagiline in Parkinson\u2019s disease. N Engl J Med 2009,361(13),1268-1278","journal-title":"N Engl J Med"},{"key":"ref=85","author":"Valldeoriola F.","year":"2017","unstructured":"Valldeoriola F.; Consenso de expertos espa\u02dcnoles sobre el uso de la safinamida en la enfermedad de Parkinson. Neurologia 2017","journal-title":"Neurologia"},{"key":"ref=86","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1111\/bph.13020","volume":"172","author":"Bonif\u00e1cio M.J.","year":"2015","unstructured":"Bonif\u00e1cio M.J.; Torr\u00e3o L.; Loureiro A.I.; Palma P.N.; Wright L.C.; Soares-da-Silva L.; Pharmacological profile of opicapone, a thirdgeneration nitrocatechol catechol-O-methyl transferase inhibitor, in the rat. Br J Pharmacol 2015,172(7),1739-1752","journal-title":"Br J Pharmacol"},{"key":"ref=87","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1136\/jnnp.74.8.1071","volume":"74","author":"Brooks D.J.","year":"2003","unstructured":"Brooks D.J.; Sagar H.; Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson\u2019s disease: A randomised, placebo controlled, double blind, six months study. J Neurol Neurosurg Psychiatry 2003,74,1071-1079","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=88","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.biopha.2016.08.009","volume":"83","author":"Po\u00f3r M.","year":"2016","unstructured":"Po\u00f3r M.; Zr\u00ednyi Z.; K\u0151szegi T.; Structure related effects of flavonoid aglycones on cell cycle progression of HepG2 cells: Metabolic activation of fisetin and quercetin by catechol-O methyltransferase (COMT). Biomed Pharmacother 2016,83,998-1005","journal-title":"Biomed Pharmacother"},{"key":"ref=89","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2147\/CIA.S3787","volume":"4","author":"Truong D.D.","year":"2009","unstructured":"Truong D.D.; Tolcapone: Review of its pharmacology and use as adjunctive therapy in patients with Parkinson\u2019s disease. Clin Interv Aging 2009,4,109-113","journal-title":"Clin Interv Aging"},{"key":"ref=90","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1002\/mds.27475","volume":"33","author":"Fabbri M.","year":"2018","unstructured":"Fabbri M.; Ferreira J.J.; Lees A.; Stocchi F.; Poewe W.; Tolosa E.; Rascol O.; Opicapone for the treatment of Parkinson\u2019s disease: A review of a new licensed medicine. Mov Disord 2018,33(10),1528-1539","journal-title":"Mov Disord"},{"key":"ref=91","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1016\/j.clinthera.2013.08.011","volume":"35","author":"Devos D.","year":"2013","unstructured":"Devos D.; Moreau C.; Dujardin K.; Cabantchik L.; Defebvre L.; Bordet R.; New pharmacological options for treating advanced Parkinson\u2019s disease. Clin Ther 2013,35(10),1640-1652","journal-title":"Clin Ther"},{"key":"ref=92","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1017\/S1461145712000715","volume":"16","author":"Bortolato M.","year":"2013","unstructured":"Bortolato M.; Godar S.C.; Alzghoul L.; Zhang J.; Darling R.D.; Kimberly L.; Simpson, K.L.; Bini, V.; Chen, K.; Wellman, C.L.; Lin, R.C.S.; Shih, J.C. Monoamine oxidase A and A\/B knockout mice display autistic-like features. Int J Neuropsychopharmacol 2013,16(4),869-888","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref=93","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1107\/S1600536812032734","volume":"68","author":"Mrad M.L.","year":"2012","unstructured":"Mrad M.L.; Zeller M.; Hernandez K.J.; Rzaigui M.; Ben Nasr C.; Bis(adamantan-1-aminium) hydrogen phosphate fumaric acid sesquisolvate. Acta Crystallogr Sect E Struct Rep Online 2012,68(Pt 8),2531-2532","journal-title":"Acta Crystallogr Sect E Struct Rep Online"},{"key":"ref=94","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1007\/s00702-018-1869-1","volume":"125","author":"Perez-Lloret S.","year":"2018","unstructured":"Perez-Lloret S.; Rascol O.; Efficacy and safety of amantadine for the treatment of -DOPA-induced dyskinesia. J Neural Transm (Vienna) 2018,125(8),1237-1250","journal-title":"J Neural Transm (Vienna)"},{"key":"ref=95","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2017\/2532764","volume":"2017","author":"Kostelnik A.","year":"2017","unstructured":"Kostelnik A.; Cegan A.; Pohanka M.; Anti-Parkinson drug biperiden inhibits enzyme acetylcholinesterase. BioMed Res Int 2017,2017,1-5","journal-title":"BioMed Res Int"},{"key":"ref=96","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.nbd.2019.01.012","volume":"125","author":"Downs A.M.","year":"2019","unstructured":"Downs A.M.; Fan X.; Donsante C.; Jinnah H.A.; Hess E.J.; Trihexyphenidyl rescues the deficit in dopamine neurotransmission in a mouse model of DYT1 dystonia. Neurobiol Dis 2019,125,115-122","journal-title":"Neurobiol Dis"}],"container-title":["Mini-Reviews in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/176367","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T09:55:23Z","timestamp":1695376523000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/176367\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,27]]},"references-count":96,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,5,27]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389557519666191104110908","relation":{},"ISSN":["1389-5575"],"issn-type":[{"value":"1389-5575","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5,27]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-12-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-04-02","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-09-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}